ReviewJournal of mammary gland biology and neoplasia2001
Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.
Review in Journal of mammary gland biology and neoplasia, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.Neuro-oncology · 2024Article
- Role of tyrosine kinases in bladder cancer progression: an overview.Cell communication and signaling : CCS · 2020Review
- Contribution of synergism between PHF8 and HER2 signalling to breast cancer development and drug resistance.EBioMedicine · 2020Article
- FOXA1 is Prognostic of Triple Negative Breast Cancers by Transcriptionally SuppressingInternational journal of biological sciences · 2019Article
- Article
- Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.Journal of proteome research · 2015Article
- Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer Cells.Breast cancer : basic and clinical research · 2015Article
- Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.PloS one · 2015Article
- An unexpected role for caspase-2 in neuroblastoma.Cell death & disease · 2014Article
- c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.Oncogene · 2014Article
- The PGC-1/ERR signaling axis in cancer.Oncogene · 2013Review
- Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Science signaling · 2013Article
- Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.Molecular cancer · 2010Article
- c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland.BMC biology · 2009Article
- Review
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene · 2007Review
- Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Article
- Of mice and Myc: c-Myc and mammary tumorigenesis.Journal of mammary gland biology and neoplasia · 2004Review
- C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.Breast cancer research : BCR · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proto-oncogene c-myc encodes a transcription factor which plays a major role in the regulation of normal cellular proliferation and is aberrantly expressed in many breast tumors. In a normal cell Myc expression levels are tightly regulated being subject to many layers of control. Errantly expressed Myc collaborates with other oncogenes to promote transformation. In this review we will focus on the association between abnormal Myc expression and mammary cancer. In particular, we will discuss the role of Myc as a downstream effector of the ErbB2 receptor tyrosine kinase which is overexpressed and constitutively activate in many mammary tumors. The cooperation between Myc and ErbB2 in transformation will be discussed in relation to clinical studies on Myc in human cancer and with consideration of transgenic models of Myc-induced mammary cancer. Data from our laboratory will be presented showing that deregulated ErbB2 activity strongly stimulates cytoplasmic signaling pathways which in turn impinge on Myc at multiple levels causing its deregulated expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.